Rationale for an early detection program for bladder cancer
- PMID: 21814313
- PMCID: PMC3142833
- DOI: 10.4103/0970-1591.82841
Rationale for an early detection program for bladder cancer
Abstract
Introduction: A total of 356,557 new cases were diagnosed annually worldwide in 2009, it was estimated that 52,810 new patients were to be diagnosed with bladder cancer and there were 10,180 projected deaths from the disease in the USA. Despite being the fourth commonest cancer in men, we do not have an early detection/screening program for bladder cancer. The review was aimed at looking at the evidence for the rationale for an early detection program for bladder cancer.
Materials and methods: A detailed search on bladder cancer epidemiology, diagnosis, pathology, tumor markers, treatment outcomes, screening, morbidity and mortality of bladder cancer was carried out on Pubmed central/Medline. Original articles, review articles, monograms, book chapters on bladder cancer, text books on urological oncology, oncology and urology were reviewed. The latest information for new articles before publication was last accessed in June 2010.
Discussion and conclusions: Bladder cancer is the fourth commonest cancer in men, the annual death rate from this disease is significant and every year there is an increase in its incidence globally. The prognosis of bladder cancer is stage and grade dependent; the lower the stage (T2 or less) the better is the survival. Delay in the diagnosis and treatment does alter the overall outcome. Therefore, there is a clear need for early detection of bladder cancer and screening program. Although we do not have an ideal marker for bladder cancer, it is time we maximize the potential of markers such as UroVysion, NMP22 along with cytology to start such a program. May be as a first step the early detection and screening program could be started in high-risk population. It is not worth waiting till we find the best marker as it would be unfair to our patients. The fear of unnecessary tests and treatment in bladder cancer after its detection in screening program is without any substance. The cost-effectiveness of such a program is certainly comparable to that is used for colon or breast and for prostate as well.
Keywords: Biomarkers; PSA; bladder cancer; early detection; high-risk population; screening; survival in bladder cancer.
Conflict of interest statement
Similar articles
-
Digital Breast Tomosynthesis with Hologic 3D Mammography Selenia Dimensions System for Use in Breast Cancer Screening: A Single Technology Assessment [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 4. Report from the Norwegian Institute of Public Health No. 2017-08. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 4. Report from the Norwegian Institute of Public Health No. 2017-08. PMID: 29553669 Free Books & Documents. Review.
-
Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040. Health Technol Assess. 2010. PMID: 20082749 Review.
-
Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jul. Report No.: 14-05210-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jul. Report No.: 14-05210-EF-1. PMID: 27583318 Free Books & Documents. Review.
-
Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188
-
The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines.BJU Int. 2011 Aug;108(4):546-52. doi: 10.1111/j.1464-410X.2010.09971.x. Epub 2011 Jan 11. BJU Int. 2011. PMID: 21223477
Cited by
-
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.J Health Econ Outcomes Res. 2024 Oct 28;11(2):109-117. doi: 10.36469/001c.124208. eCollection 2024. J Health Econ Outcomes Res. 2024. PMID: 39479557 Free PMC article.
-
Elevated phospholipase A2 activities in plasma samples from multiple cancers.PLoS One. 2013;8(2):e57081. doi: 10.1371/journal.pone.0057081. Epub 2013 Feb 22. PLoS One. 2013. PMID: 23451150 Free PMC article.
-
Study of Proliferating cell nuclear antigen expression and Angiogenesis in Urothelial neoplasms: Correlation with tumor grade and stage.Urol Ann. 2018 Apr-Jun;10(2):209-214. doi: 10.4103/UA.UA_167_17. Urol Ann. 2018. PMID: 29719336 Free PMC article.
-
Comparative Review on Cancer Pathology from Aberrant Histone Chaperone Activity.Int J Mol Sci. 2024 Jun 10;25(12):6403. doi: 10.3390/ijms25126403. Int J Mol Sci. 2024. PMID: 38928110 Free PMC article. Review.
-
Pathological Characteristics of Primary Bladder Carcinoma Treated at a Tertiary Care Hospital and Changing Demographics of Bladder Cancer in Sri Lanka.Adv Urol. 2016;2016:5751647. doi: 10.1155/2016/5751647. Epub 2016 Jan 14. Adv Urol. 2016. PMID: 26884756 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–49. - PubMed
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
-
- Thalmann GN, Stein JP. Outcomes of radical cystectomy. BJU Int. 2008;102:1279–88. - PubMed
-
- Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med. 1990;332:1129–38. - PubMed
-
- Lokeshwar VB, Soloway MS. Current bladder tumour tests: Does their projected utility fulfill clinical necessity? J Urol. 2001;165:1067–77. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous